Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8877168 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul, 2023
(6 months from now) | |
US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(1 year, 11 months from now) |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Feb 22, 2022 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(7 years from now) | |
US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(7 years from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8636713 | BAUSCH AND LOMB INC | Methods and devices for drug delivery to ocular tissue using microneedle |
May, 2027
(4 years from now) | |
US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(10 years from now) | |
US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic